Golden Leaf Competitors

Golden Leaf (OTCMKTS:GLDFF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Analyst Ratings

This is a breakdown of current ratings for Golden Leaf and Abacus Health Products, as provided by MarketBeat.

Valuation & Earnings

This table compares Golden Leaf and Abacus Health Products' gross revenue, earnings per share and valuation.

Profitability

This table compares Golden Leaf and Abacus Health Products' net margins, return on equity and return on assets.

Golden Leaf (OTCMKTS:GLDFF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Analyst Ratings

This is a breakdown of current ratings for Golden Leaf and Acreage, as provided by MarketBeat.

Acreage has a consensus price target of $8.4333, suggesting a potential upside of 204.45%. Given Acreage's higher possible upside, analysts clearly believe Acreage is more favorable than Golden Leaf.

Valuation & Earnings

This table compares Golden Leaf and Acreage's gross revenue, earnings per share and valuation.

Profitability

This table compares Golden Leaf and Acreage's net margins, return on equity and return on assets.

Summary

Acreage beats Golden Leaf on 2 of the 2 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and Golden Leaf (OTCMKTS:GLDFF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Applied Biosciences and Golden Leaf, as reported by MarketBeat.com.

Earnings & Valuation

This table compares Applied Biosciences and Golden Leaf's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Applied Biosciences and Golden Leaf's net margins, return on equity and return on assets.

Ayr Strategies (OTCMKTS:AYRSF) and Golden Leaf (OTCMKTS:GLDFF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Ayr Strategies and Golden Leaf, as reported by MarketBeat.com.

Ayr Strategies currently has a consensus target price of $34.8571, suggesting a potential upside of 63.96%. Given Ayr Strategies' higher possible upside, analysts plainly believe Ayr Strategies is more favorable than Golden Leaf.

Earnings & Valuation

This table compares Ayr Strategies and Golden Leaf's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Ayr Strategies and Golden Leaf's net margins, return on equity and return on assets.

Summary

Ayr Strategies beats Golden Leaf on 2 of the 2 factors compared between the two stocks.

Can B (NASDAQ:CANB) and Golden Leaf (OTCMKTS:GLDFF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Can B and Golden Leaf, as reported by MarketBeat.

Valuation & Earnings

This table compares Can B and Golden Leaf's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Can B and Golden Leaf's net margins, return on equity and return on assets.

Cansortium (OTCMKTS:CNTMF) and Golden Leaf (OTCMKTS:GLDFF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Cansortium and Golden Leaf, as reported by MarketBeat.

Cansortium currently has a consensus target price of $1.20, suggesting a potential upside of 39.67%. Given Cansortium's higher possible upside, equities analysts clearly believe Cansortium is more favorable than Golden Leaf.

Valuation & Earnings

This table compares Cansortium and Golden Leaf's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Cansortium and Golden Leaf's net margins, return on equity and return on assets.

Summary

Cansortium beats Golden Leaf on 2 of the 2 factors compared between the two stocks.